This week, we provide top-five ranked VE data for our Medical stocks. We take a look at our latest data on Twitter TWTR$ and provide a free download link for our stock report on the company.
VALUATION WATCH: Overvalued stocks now make up 61.01% of our stocks assigned a valuation and 26.54% of those equities are calculated to be overvalued by 20% or more. Fourteen sectors are calculated to be overvalued. Because overvaluation is now calculated to be above 60%, we have re-instituted our valuation watch.
ValuEngine Index Overview
| Index | Week Open | Friday PM | Change | % Change | YTD |
| DJIA | 22827.65 | 22887.92 | 60.27 | 0.26% | 15.81% |
| NASDAQ | 6586.73 | 6613.93 | 27.2 | 0.41% | 22.86% |
| RUSSELL 2000 | 1507.91 | 1505.19 | -2.72 | -0.18% | 10.91% |
| S&P 500 | 2550.62 | 2556.79 | 6.17 | 0.24% | 14.20% |
ValuEngine Market Overview
| Summary of VE Stock Universe | |
| Stocks Undervalued | 38.99% |
| Stocks Overvalued | 61.01% |
| Stocks Undervalued by 20% | 18.44% |
| Stocks Overvalued by 20% | 26.54% |
ValuEngine Sector Overview
| Sector | Change | MTD | YTD | Valuation | Last 12-MReturn | P/E Ratio |
| Aerospace | -0.41% | 1.15% | 16.10% | 28.99% overvalued | 35.00% | 23.08 |
| Computer and Technology | -0.08% | 2.55% | 27.12% | 15.98% overvalued | 22.39% | 33.17 |
| Industrial Products | 0.22% | 1.54% | 14.59% | 15.11% overvalued | 26.21% | 25.61 |
| Utilities | 0.02% | 1.56% | 23.82% | 10.64% overvalued | 17.61% | 23.42 |
| Multi-Sector Conglomerates | 0.14% | 0.65% | 12.55% | 10.30% overvalued | 14.16% | 20.51 |
| Auto-Tires-Trucks | -0.40% | 2.16% | 28.26% | 10.14% overvalued | 34.13% | 14.99 |
| Finance | -0.17% | 1.28% | 11.17% | 9.88% overvalued | 17.45% | 18.85 |
| Construction | -0.33% | 0.44% | 21.47% | 9.54% overvalued | 27.19% | 22.54 |
| Consumer Discretionary | -0.55% | 0.41% | 14.65% | 7.07% overvalued | 18.29% | 25.26 |
| Business Services | 0.20% | 1.40% | 10.61% | 6.18% overvalued | 9.64% | 26.64 |
| Transportation | 0.12% | 0.60% | 17.98% | 5.37% overvalued | 22.52% | 23.22 |
| Consumer Staples | -0.01% | 1.34% | 7.16% | 4.79% overvalued | 8.36% | 26.08 |
| Basic Materials | 0.18% | 1.91% | 17.32% | 3.53% overvalued | 16.76% | 28.19 |
| Medical | -0.65% | 0.05% | 22.60% | 3.44% overvalued | 12.36% | 29.01 |
| Retail-Wholesale | -0.94% | -1.63% | 1.44% | 4.71% undervalued | 4.03% | 23.29 |
| Oils-Energy | -0.70% | -1.21% | 2.34% | 12.20% undervalued | -5.48% | 28.65 |
Sector Talk–Medical
Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service. Top- five lists are provided for each category. We applied some basic liquidity criteria–share price greater than $3 and average daily volume in excess of 100k shares.
Top-Five Medical Stocks–Short-Term Forecast Returns
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| GILD | GILEAD SCIENCES | 81.3 | 12.26% | 11.32% |
| AZN | ASTRAZENECA PLC | 34.53 | 9.62% | 12.11% |
| ANTM | ANTHEM INC | 189.74 | 12.60% | 57.00% |
| PDLI | PDL BIOPHARMA | 3.45 | -40.70% | 6.48% |
| MYL | MYLAN NV | 37.76 | -20.34% | 1.86% |
Top-Five Medical Stocks–Momentum
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| CALA | CALITHERA BIOSC | 17.6 | N/A | 494.59% |
| CBAY | CYMABAY THERAPT | 8.67 | 63.17% | 407.02% |
| IMMU | IMMUNOMEDICS | 11.59 | 72.38% | 363.60% |
| ESPR | ESPERION THERAP | 55.54 | 167.71% | 350.81% |
| AVEO | AVEO PHARMACEUT | 3.68 | 74.39% | 343.37% |
Top-Five Medical Stocks–Composite Score
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| INVA | INNOVIVA INC | 13.9 | -33.86% | 38.58% |
| MYL | MYLAN NV | 37.76 | -20.34% | 1.86% |
| ANTM | ANTHEM INC | 189.74 | 12.60% | 57.00% |
| AET | AETNA INC-NEW | 154.49 | 6.56% | 39.97% |
| SNY | SANOFI-AVENTIS | 49.74 | 6.22% | 31.07% |
Top-Five Medical Stocks–Most Overvalued
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| CYH | COMMNTY HLTH SY | 6.01 | 300.00% | -42.54% |
| VIVE | VIVEVE MEDICAL | 5.49 | 300.00% | -18.79% |
| CLSN | CELSION CORP | 5.15 | 300.00% | -68.30% |
| LJPC | LA JOLLA PHARMA | 35.08 | 218.69% | 70.29% |
| CASI | CASI PHARMACEUT | 3.64 | 199.06% | 134.84% |
Free Download for Readers
As a bonus to our Free Weekly Newsletter subscribers,
we are offering a FREE DOWNLOAD of one of our Stock Reports
Twitter (TWTR) is a public, real-time, global platform where any user can create a Tweet and any user can follow other users. The platform is unique in its simplicity: Tweets are limited to 140 characters of text. This constraint makes it easy for anyone to quickly create, distribute and discover content that is consistent across our platform and optimized for mobile devices. As a result, Tweets drive a high velocity of information exchange that makes Twitter uniquely live.
VALUENGINE RECOMMENDATION: ValuEngine continues its SELL recommendation on TWITTER INC for 2017-10-12. Based on the information we have gathered and our resulting research, we feel that TWITTER INC has the probability to UNDERPERFORM average market performance for the next year. The company exhibits UNATTRACTIVE Sharpe Ratio and Price Sales Ratio.
You can download a free copy of detailed report on Twitter (TWTR) from the link below.
Read our Complete Rating and Forecast Report HERE.
| ValuEngine Forecast | ||
| Target Price* |
Expected Return |
|
|---|---|---|
| 1-Month | 18.35 | -0.52% |
| 3-Month | 17.91 | -2.94% |
| 6-Month | 17.36 | -5.90% |
| 1-Year | 17.29 | -6.29% |
| 2-Year | 14.11 | -23.53% |
| 3-Year | 12.50 | -32.26% |
| Valuation & Rankings | |||
| Valuation | 28.63% undervalued | Valuation Rank(?) | 87 |
| 1-M Forecast Return | -0.52% | 1-M Forecast Return Rank | 17 |
| 12-M Return | 2.22% | Momentum Rank(?) | 39 |
| Sharpe Ratio | -0.47 | Sharpe Ratio Rank(?) | 18 |
| 5-Y Avg Annual Return | -23.53% | 5-Y Avg Annual Rtn Rank | 20 |
| Volatility | 50.47% | Volatility Rank(?) | 33 |
| Expected EPS Growth | 107.69% | EPS Growth Rank(?) | 86 |
| Market Cap (billions) | 11.71 | Size Rank | 90 |
| Trailing P/E Ratio | n/a | Trailing P/E Rank(?) | 28 |
| Forward P/E Ratio | 1,845.00 | Forward P/E Ratio Rank | 1 |
| PEG Ratio | 1.32 | PEG Ratio Rank | 37 |
| Price/Sales | 4.77 | Price/Sales Rank(?) | 23 |
| Market/Book | 3.37 | Market/Book Rank(?) | 38 |
| Beta | 1.02 | Beta Rank | 39 |
| Alpha | -0.46 | Alpha Rank | 12 |
ValuEngine.com is an Independent Research Provider (IRP), producing buy/hold/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.
Contact ValuEngine at (800) 381-5576 or support@valuengine.com
Visit www.ValuEngine.com for more information
ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuEngine’s award-winning stock research.
Contact ValuEngine Capital at info@valuenginecapital.com
Visit www.ValuEngineCapital.com for more information